Compare Heron Therapeutics Inc (HRTX) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Marsh & McLennan Companies, Inc. trades at $181.86 (market cap $87.77B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 959.7× Heron Therapeutics Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.17% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | MRSH | |
|---|---|---|
Market Cap | $91.46M | $87.77B |
Sector | Health | Financials |
52-Week High | $1.96 | $211.21 |
52-Week Low | $0.39 | $157.32 |
Enterprise Value | $189.36M | $108.61B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Marsh (MRSH) trades at $181.79, down slightly (-0.21%) on the day. The stock exhibits a bullish technical trend with strong moving average signals, while fundamentals are solid with consistent revenue growth to $26.98B in 2025 and a robust net income margin of 14.26%. Recent news highlights a 10% dividend increase to $0.99 per share and strategic partnerships expanding its advisory business. The company has beaten earnings estimates for the last three consecutive quarters.
The outlook for MRSH is positive, supported by earnings momentum and shareholder returns, though rising operating expenses and a premium valuation (P/E of 22.77) present near-term risks. Analyst consensus is a 'Hold' with a $203.75 price target, suggesting modest upside potential from current levels, but investor sentiment is tempered by cost pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
